25,612 results match your criteria Radiation Therapy Prostate Cancer


A mixed-integer linear programming optimization model framework for capturing expert planning style in low dose rate prostate brachytherapy.

Phys Med Biol 2019 Feb 15. Epub 2019 Feb 15.

Mechanical Engineering, University of Alberta, Edmonton, Alberta, CANADA.

Low dose rate (LDR) brachytherapy is a minimally invasive form of radiation therapy, used to treat prostate cancer, and it involves permanent implantation of radioactive sources (seeds) inside of the prostate gland. Treatment planning in brachytherapy involves a decision making process for the placement of the sources in order to deliver an effective dose of radiation to cancerous tissue in the prostate while sparing the surrounding healthy tissue. Such a decision making process can be modeled as a mixed-integer linear programming (MILP) problem. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6560/ab075cDOI Listing
February 2019

[Local radiotherapy for patients with newly diagnosed, metastatic prostate cancer].

Strahlenther Onkol 2019 Feb 14. Epub 2019 Feb 14.

Department of Radiation Oncology, Competence Center Palliative Care, University Hospital Zurich (USZ), Rämistrasse 100, 8091, Zurich, Schweiz.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-019-01435-8DOI Listing
February 2019

Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial.

JAMA Oncol 2019 Feb 14. Epub 2019 Feb 14.

Henry Ford Hospital, Detroit, Michigan.

Importance: Hypofractionated radiotherapy (HRT) would be more convenient for men with low-risk prostate cancer and cost less than conventional radiotherapy (CRT) as long as HRT is noninferior to CRT in terms of survival and quality of life (QOL) is not found to be worse.

Objective: To assess differences in QOL between men with low-risk prostate cancer who are treated with HRT vs CRT.

Design, Setting, And Participants: In this phase 3 randomized clinical trial, men with low-risk prostate cancer were enrolled from sites within the National Cancer Institute's National Clinical Trials Network in the United States, Canada, and Switzerland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.6752DOI Listing
February 2019

[Magnetic resonance imaging in the diagnosis of recurrent prostate cancer].

Urologiia 2018 Oct(4):172-178

I.M. Sechenov First MSMU of Minzdrav of Russia, Moscow, Russia.

The article reviews the domestic and international literature on local recurrence of prostate cancer both after surgery and non-invasive treatments. The authors describe modern high-precision techniques used in magnetic resonance imaging that are used today in clinical practice for the most accurate detection of recurrent prostate cancer lesions. Read More

View Article

Download full-text PDF

Source
October 2018

Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation.

Front Immunol 2018 25;9:3169. Epub 2019 Jan 25.

John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.

Although immunotherapy has emerged as the "next generation" of cancer treatments, it has not yet been shown to be successful in the treatment of patients with prostate cancer, for whom therapeutic options remain limited to radiotherapy and androgen (hormone) deprivation therapy. Previous studies have shown that priming natural killer (NK) cells isolated from healthy individuals via co-incubation with CTV-1 cells derived from an acute lymphoblastic leukemia (ALL) enhances their cytotoxicity against human DU145 (metastatic) prostate cancer cells, but it remains unknown to what extent NK cells from patients with prostate cancer can be triggered to kill. Herein, we explore the phenotype of peripheral blood NK cells in patients with prostate cancer and compare the capacity of CTV-1 cell-mediated priming and IL-2 stimulation to trigger NK cell-mediated killing of the human PC3 (metastatic) prostate cancer cell line. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.03169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362408PMC
January 2019

Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.

J Urol 2019 Mar;201(3):528-534

Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.

Purpose: The aim of this guideline is to present recommendations regarding moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) radiation therapy for localized prostate cancer.

Methods And Materials: The American Society for Radiation Oncology convened a task force to address 8 key questions on appropriate indications and dose-fractionation for moderately and ultrahypofractionated radiation therapy, as well as technical issues, including normal tissue dose constraints, treatment volumes, and use of image guided and intensity modulated radiation therapy. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and Society-approved tools for grading evidence quality and recommendation strength. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000071DOI Listing

Improving fiducial and prostate capsule visualization for radiotherapy planning using MRI.

J Appl Clin Med Phys 2019 Feb 12. Epub 2019 Feb 12.

The Royal Marsden Hospital NHS Foundation Trust, London, UK.

Background And Purpose: Intraprostatic fiducial markers (FM) improve the accuracy of radiotherapy (RT) delivery. Here we assess geometric integrity and contouring consistency using a T2*-weighted (T2*W) sequence alone, which allows visualization of the FM.

Material And Methods: Ten patients scanned within the Prostate Advances in Comparative Evidence (PACE) trial (NCT01584258) had prostate images acquired with computed tomography (CT) and Magnetic Resonance (MR) Imaging: T2-weighted (T2W) and T2*W sequences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acm2.12529DOI Listing
February 2019

Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy: A psychological perspective.

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31980DOI Listing
February 2019
1 Read

Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.

Eur Urol Focus 2019 Feb 7. Epub 2019 Feb 7.

Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address:

One of the standard management options for high-risk localized prostate cancer is radiotherapy combined with long-term androgen deprivation therapy. Trials involving chemotherapy or next-generation hormone therapies in combination with a local treatment are ongoing for this specific subgroup. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.01.015DOI Listing
February 2019
1 Read

Long-Term Implications of a Positive Post Treatment Biopsy Among Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.

J Urol 2019 Feb 5. Epub 2019 Feb 5.

From the Department of Radiation Oncology, Department of Pathology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, N,Y., N.Y. 10065.

Purpose: To determine the prognostic importance of a positive post-treatment biopsy after prostate radiotherapy.

Materials And Methods: 382 patients underwent a post-treatment biopsy after external beam radiotherapy (EBRT) for clinically localized prostate cancer. Post-treatment biopsies were classified as positive (prostatic adenocarcinoma without typical radiation-induced changes), negative (no evidence of carcinoma) or adenocarcinoma with severe treatment effect (STE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000110DOI Listing
February 2019
1 Read

A systematic review of radiation-induced testicular toxicities following radiotherapy for prostate cancer.

J Cell Physiol 2019 Feb 10. Epub 2019 Feb 10.

Neurogenic Inflammation Research Center, Mashhad University of Medical Science, Mashhad, Iran.

Background: Prostate cancer is the second most common malignancy in men in the world, and radiotherapy is used as a standard treatment modality for this cancer. Although this treatment modality effectively kills prostate cancerous cells, it unavoidably irradiates the organs/tissues that are away from the treatment site. In this regard, radiation-induced testicular toxicities following prostate radiotherapy can affect sexual function, reproduction, and quality of life in cancer survivors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28283DOI Listing
February 2019
2 Reads

Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer.

Urol Oncol 2019 Feb 6. Epub 2019 Feb 6.

Therapeutic Radiology, Yale University School of Medicine, New Haven, CT. Electronic address:

For prostate cancer radiation therapy, daily sessions spanning approximately 2 months has been considered the standard of care for patients managed with curative intent. In recent years, data has emerged which supports the use of higher dose per fraction schemes leading to a reduced duration of treatment. This form of radiation-generally termed moderate hypofractionation or stereotactic body radiation therapy-increasingly appears to be a safe and effective alternative to the conventional course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.01.015DOI Listing
February 2019
1 Read

Prostate brachytherapy with iodine-125 seeds: analysis of a single institutional cohort.

Int Braz J Urol 2019 Jan 25;45. Epub 2019 Jan 25.

Departamento de Radioterapia, Hospital Sirio-Libanês, São Paulo, SP, Brasil.

Objectives: Brachytherapy (BT) with iodine-125 seeds placement is a consolidated treatment for prostate cancer. The objective of this study was to assess the clinical outcomes in patients with prostate cancer who underwent low-dose-rate (LDR) -BT alone in a single Brazilian institution.

Materials And Methods: Patients treated with iodine-125 BT were retrospectively assessed after at least 5 years of follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0142DOI Listing
January 2019
1 Read

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.

JAMA Netw Open 2019 Feb 1;2(2):e188006. Epub 2019 Feb 1.

Department of Radiation Oncology, University of California, Los Angeles.

Importance: Stereotactic body radiotherapy harnesses improvements in technology to allow the completion of a course of external beam radiotherapy treatment for prostate cancer in the span of 4 to 5 treatment sessions. Although mounting short-term data support this approach, long-term outcomes have been sparsely reported.

Objective: To assess long-term outcomes after stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2018.8006DOI Listing
February 2019
1 Read

Prostate cancer and subsequent nutritional outcomes: the role of diagnosis and treatment.

J Cancer Surviv 2019 Feb 7. Epub 2019 Feb 7.

Massey Cancer Center, Department of Radiation Oncology, Virginia Commonwealth University Health System, Box 980058, Richmond, VA, 23298, USA.

Purpose: To comprehensively explore the role of a prostate cancer diagnosis and its treatment to several outcomes including diet, Hemoglobin A1c, and weight status, in a large, nationally representative, cross-sectional study.

Methods: This analysis used five cross sections from the publicly available National Health and Nutrition Evaluation Survey (NHANES) from 2001 to 2010. A sample of 289 men with a history of prostate cancer was matched to a comparison group of 655 men with elevated prostate-specific antigen (> 4 ng/mL) but no reported diagnosis of prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11764-019-00739-zDOI Listing
February 2019
1 Read

Impact of high dose volumetric CT on PTV margin reduction in VMAT prostate radiotherapy.

Phys Med Biol 2019 Feb 7. Epub 2019 Feb 7.

Princess Margaret/Techna, University Health Network, 190 Elizabeth St., Rm 1S-411, Toronto, Ontario, M5G 2C4, CANADA.

The aim of the study is to determine PTV margin for inter-observer variability in the volumetric modulated arc therapy (VMAT) prostate radiotherapy with high-dose volumetric CT (HDVCT) and conventional helical CT (CCT) for planning. Secondly to investigate the impact of geometric (PTV expansion) and dosimetric (conformity) imperfection of planning process on the PTV margin analysis. Prostate gland of ten patients were scanned with CCT and HDVCT techniques consecutively on a 320 slice volumetric CT scanner with wide field detector of 16 cm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6560/ab050fDOI Listing
February 2019
1 Read

Decision Support Systems in Oncology.

JCO Clin Cancer Inform 2019 Feb(3):1-9

1 Maastricht University, Maastricht, the Netherlands.

Precision medicine is the future of health care: please watch the animation at https://vimeo.com/241154708 . As a technology-intensive and -dependent medical discipline, oncology will be at the vanguard of this impending change. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.18.00001DOI Listing
February 2019
1 Read

Radiosensitivity: Gender and Order of Administration of G-CSF, An Experimental Study in Mice.

Radiat Res 2019 Feb 7. Epub 2019 Feb 7.

Department of a   Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

To elucidate the potential influence of stimulating bone marrow before cell-cycle-dependent irradiation, we sought to determine overall survival in mice receiving total-body irradiation (TBI) when administered granulocyte stimulating factor (G-CSF) at different time points. Gender differences were also studied. C57/BL/6J mice, aged 9-14 weeks, received 8 Gy TBI in a perspex cage using a linear accelerator. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1667/RR15038.1DOI Listing
February 2019
2 Reads

Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers.

Asia Pac J Clin Oncol 2019 Feb 6. Epub 2019 Feb 6.

Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China.

Men with prostate cancer with positive margins, extraprostatic extension, positive lymph nodes, high prostate-specific antigen, or high Gleason Score are at high risk of recurrence following primary therapy. Androgen deprivation therapy (ADT), which includes medical/surgical castration, antiandrogen therapy, and combined androgen blockade, can be combined with primary therapy to shrink the tumor, reduce margin positivity, and reduce the risk of recurrence. However, many problems still remain, such as optimizing the application of ADT in the treatment of prostate cancer, for example, ideal patient population and optimal timing and duration of therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13108DOI Listing
February 2019
1 Read

Glutathione, an antioxidant tripeptide: Dual roles in Carcinogenesis and Chemoprevention.

Curr Protein Pept Sci 2019 Feb 6. Epub 2019 Feb 6.

Postgraduate & Research Department of Zoology, St. Joseph's College (Autonomous), Devagiri (Affiliated to University of Calicut), Calicut- 673 019, Kerala. India.

Glutathione (GSH or reduced glutathione) is a tripeptide of gamma-Glutamyl-cysteinyl-glycine and the predominant intracellular antioxidant in many organisms including humans. GSH and associated enzymes are controlled by a transcription factor-nuclear factor-2 related erythroid factor-2 (Nrf2). In cellular milieu, GSH protects the cells essentially against a wide variety of free radicals including reactive oxygen species, lipid hydroperoxides, xenobiotic toxicants, and heavy metals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389203720666190206130003DOI Listing
February 2019
1 Read

Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.

Am J Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Department of Radiation Oncology, Beaumont Hospital, Dearborn, MI.

Objectives: We applied an established prognostic model to high-risk prostate cancer (HRPC) patients treated with radiotherapy (RT) and evaluated the influence of clinical and treatment variables on treatment outcomes.

Methods: In total, 1075 HRPC patients undergoing definitive radiotherapy (RT) between 1995 and 2010 were retrospectively reviewed. Median follow-up was 62. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000521DOI Listing
February 2019
2 Reads

Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase I/II trial for Patients with Low and Intermediate-Risk Prostate Cancer.

Int J Radiat Oncol Biol Phys 2019 Feb 2. Epub 2019 Feb 2.

Introduction: This study presents a prospective phase I, IRB-approved dose-escalated stereotactic body radiotherapy (SBRT) trial for prostate cancer (CaP) to assess the impact of dose level on quality of life, toxicity, and clinical outcomes.

Materials/methods: From 2011-2016, 26 patients with low and intermediate-risk CaP received 40, 45, and 50 Gy in five fractions to the prostate in cohorts of 9, 10, and 7 patients. Self-reported QOL was prospectively measured from the Expanded Prostate Cancer Index Composite (EPIC) and American Urological Association (AUA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.01.092DOI Listing
February 2019
1 Read

Ten-year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiotherapy for localized prostate cancer.

Int J Radiat Oncol Biol Phys 2019 Feb 2. Epub 2019 Feb 2.

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address:

Purpose/objectives: Long term outcomes with hypofractionated radiotherapy for prostate cancer are limited. We report 10-year outcomes for patients treated with intensity modulated radiation therapy (IMRT) for localized prostate cancer with 70 Gy in 28 fractions at 2.5 Gy/fraction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.01.091DOI Listing
February 2019
1 Read

Technical note: In silico and experimental evaluation of two leaf-fitting algorithms for MLC tracking based on exposure error and plan complexity.

Med Phys 2019 Feb 5. Epub 2019 Feb 5.

ACRF Image X Institute, Sydney Medical School, University of Sydney, Australia.

Purpose: Multi-leaf collimator (MLC) tracking is being clinically pioneered to continuously compensate for thoracic and pelvic motion during radiotherapy. The purpose of this work is to characterize the performance of two MLC leaf-fitting algorithms, direct optimization and piecewise optimization, for real-time motion compensation with different plan complexity and tumor trajectories.

Methods: To test the algorithms, both in silico and phantom experiments were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.13425DOI Listing
February 2019
2 Reads

Multimodal treatments for advanced prostate cancer.

Oncotarget 2019 Jan 8;10(3):255-256. Epub 2019 Jan 8.

Thomas L. Jang: Section of Urologic Oncology, Division of Urology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26525DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349456PMC
January 2019
1 Read

The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States.

J Oncol 2019 2;2019:8170428. Epub 2019 Jan 2.

Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.

Background: Until recently, dose intensified radiotherapy was the standard radiation method for localized prostate cancer. Multiple studies have demonstrated similar efficacy and tolerability with moderate hypofractionation. In recent years there has been an increasing focus placed on understanding the cost and value of cancer care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8170428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334370PMC
January 2019
1 Read

Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer.

Clin Oncol (R Coll Radiol) 2019 Feb 1. Epub 2019 Feb 1.

Department of Radiation Oncology, Tata Medical Center, Kolkata, India.

Aims: Node-positive prostate cancer is a unique subgroup, with varied practice on locoregional treatment. Definitive treatment with hypofractionated radiotherapy has not been widely reported. We have routinely used standard regimens of hypofractionated radiotherapy for node-positive disease and report our results of toxicity, biochemical control and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clon.2019.01.004DOI Listing
February 2019
1 Read

miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition.

J Exp Clin Cancer Res 2019 Feb 4;38(1):51. Epub 2019 Feb 4.

Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Amadeo 42, 20133, Milan, Italy.

Background: Radiotherapy is one of the main treatment options for non-metastatic prostate cancer (PCa). Although treatment technical optimization has greatly improved local tumor control, a considerable fraction of patients still experience relapse due to the development of resistance. Radioresistance is a complex and still poorly understood phenomenon involving the deregulation of a variety of signaling pathways as a consequence of several genetic and epigenetic abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1060-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360656PMC
February 2019
3 Reads

Voxel-based analysis for identification of urethro-vesical subregions predicting urinary toxicity after prostate cancer radiotherapy.

Int J Radiat Oncol Biol Phys 2019 Feb 1. Epub 2019 Feb 1.

Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France. Electronic address:

Background And Purpose: To apply a voxel-based analysis to identify urethro-vesical symptom-related subregions (SRSs) associated with acute and late urinary toxicity in prostate cancer radiotherapy.

Materials And Methods: A total of 272 prostate cancer patients treated with IMRT/IGRT were prospectively analyzed. Each patient's CT was spatially normalized to a common coordinate system (CCS) via nonrigid registration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.01.088DOI Listing
February 2019
1 Read

Testosterone Profiles After Brachytherapy for Localized Prostate Cancer.

Urology 2019 Feb 1. Epub 2019 Feb 1.

Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.

Objective: To evaluate patients' serum total testosterone levels (STLs) after brachytherapy (BT) for prostate cancer.

Methods: We enrolled 102 men who underwent permanent interstitial BT using I without androgen deprivation therapy for localized prostate cancer. Seed BT radiation dose was 145 Gy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2019.01.022DOI Listing
February 2019
1 Read

Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions.

Curr Med Chem 2019 Feb 1. Epub 2019 Feb 1.

Medical Isotopes Program, Isotope Development Group, MS 6229, Bldg. 4501, Oak Ridge National Laboratory, PO Box 2008, 1 Bethel Valley Road, Oak Ridge, TN, 37831. United States.

Bone pain arising from secondary skeletal malignancy constitutes one of the most common types of chronic pain among patients with cancer which can lead to rapid deterioration in quality of life. Radionuclide therapy using bone-seeking radiopharmaceuticals based on the concept of localization of the agent at the bone metastases sites to deliver focal cytotoxic levels of radiation emerged as an effective treatment modality for the palliation of symptomatic bone metastases. Bone-seeking radiopharmaceuticals not only provide palliative benefit but also improve clinical outcomes in term of overall and progression-free survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/0929867326666190201142814DOI Listing
February 2019
1 Read

Further application of hyperbaric oxygen in prostate cancer.

Med Gas Res 2018 Oct-Dec;8(4):167-171. Epub 2019 Jan 9.

Department Department of Urology and Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.

Hyperbaric oxygen therapy (HBOT) has been used as an adjuvant treatment for multiple pathological states, which involves hypoxic conditions. Over the past 50 years, HBOT has been recommended and used in a wide variety of medical conditions, clinically in the treatment of ischemic or nonhealing wounds and radiation-injured tissue, and in the treatment of malignancy. The mechanism of this treatment is providing oxygen under pressure which is higher than the atmosphere thus increasing tissue oxygen concentration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2045-9912.248268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352573PMC
January 2019
1 Read

Dose evaluation of MRI-based synthetic CT generated using a machine learning method for prostate cancer radiotherapy.

Med Dosim 2019 Jan 31. Epub 2019 Jan 31.

Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA. Electronic address:

Magnetic resonance imaging (MRI)-only radiotherapy treatment planning is attractive since MRI provides superior soft tissue contrast over computed tomographies (CTs), without the ionizing radiation exposure. However, it requires the generation of a synthetic CT (SCT) from MRIs for patient setup and dose calculation. In this study, we aim to investigate the accuracy of dose calculation in prostate cancer radiotherapy using SCTs generated from MRIs using our learning-based method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.meddos.2019.01.002DOI Listing
January 2019
2 Reads

Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements-a clinicopathologic and genomic sequencing-based discussion.

Med Oncol 2019 Feb 2;36(3):27. Epub 2019 Feb 2.

Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, USA.

Histologic variants are uncommon but well reported amongst cases of prostatic adenocarcinoma, including those in the setting of hormonal and/or chemoradiation therapy and castration resistance. However, the spectrum of morphologic phenotypes and molecular alterations present in such histologic variants are still incompletely understood. Herein, we describe a case of metastatic prostatic adenocarcinoma with hormonal and chemoradiation therapy-associated differentiation, displaying a combination of squamous cell, small cell, and sarcomatoid elements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-019-1250-8DOI Listing
February 2019
1 Read

Complications, oncological and functional outcomes of salvage treatment options following focal therapy for localized prostate cancer: a systematic review and a comprehensive narrative review.

World J Urol 2019 Feb 1. Epub 2019 Feb 1.

Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.

Background: Whether focal therapy (FT) jeopardizes subsequent prostate cancer (PCa) salvage treatments, when needed, remains a major concern and is largely unknown.

Objectives: To describe and report safety, oncological and functional outcomes of salvage treatments following PCa recurrence and/or persistence after FT.

Materials And Methods: A systematic review on salvage treatments for PCa recurrence/persistence after FT was carried out according to the PRISMA guidelines using an 'a priori protocol'. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-02642-9DOI Listing
February 2019
1 Read

Combined-modality J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects.

World J Urol 2019 Feb 1. Epub 2019 Feb 1.

CURAVID Radiology and Radiotherapy, Luebeck, Germany.

Purpose: To analyze outcomes and complication rates in an unselected cohort of men with unfavorable (NCCN intermediate and high-risk) PCa receiving combined-modality radiation treatment (CRT).

Methods: Patients received androgen deprivation therapy for 1 year and combined-modality radiation treatment (CRT) consisting of external-beam radiotherapy (EBRT, 59.4 Gy, 33 fractions) and J seed-brachytherapy (S-BT, 100 Gy). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-02649-2DOI Listing
February 2019
1 Read

Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models.

JAMA Netw Open 2019 Feb 1;2(2):e187765. Epub 2019 Feb 1.

Department of Biostatistics, University of Michigan, Ann Arbor.

Importance: Whether surgery or radiotherapy is the preferred treatment for patients with localized prostate cancer continues to be debated, and randomized clinical trials cannot yet fully address this question. Furthermore, there may be heterogeneity in responses, and the optimal treatment for a patient will depend on his clinical and tumor characteristics.

Objectives: To use a unified statistical approach to compare the association of surgery and radiotherapy with both metastatic clinical failure (CF) and survival in localized prostate cancer and to develop an online calculator for individualized, treatment-specific outcome prediction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2018.7765DOI Listing
February 2019
1 Read

Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.

Curr Top Med Chem 2019 Jan 31. Epub 2019 Jan 31.

Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, 610041, Chengdu. China.

Background: Prostate cancer (PCa) is the most common sex-related malignancy with high mortality in men worldwide. Prostate-specific membrane antigen (PSMA) is overexpressed on the surface of most prostate tumor cells and considered a valuable target for both the diagnosis and therapy of prostate cancer. A series of radiolabeled agents have been developed based on the featured PSMA ligands in the previous decade and have demonstrated promising outcomes in clinical research of primary and recurrent PCa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568026619666190201100739DOI Listing
January 2019
10 Reads

Bevacizumab is associated with delayed anastomotic leak after low anterior resection with preoperative radiotherapy for rectal cancer: a case report.

Surg Case Rep 2019 Jan 31;5(1):14. Epub 2019 Jan 31.

Department of Surgery, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitamashi, Saitamaken, 330-8503, Japan.

Background: Bevacizumab is an anti-angiogenesis agent used to treat patients with metastatic colorectal cancer and is associated with a variety of complications. We present a patient with rectal cancer who developed a delayed anastomotic leak more than 5 years after undergoing low anterior resection.

Case Report: A 78-year-old man with hematochezia was diagnosed with two synchronous rectal cancers 7 years prior to presentation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0573-1DOI Listing
January 2019
1 Read

A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?

World J Urol 2019 Jan 31. Epub 2019 Jan 31.

Urology Department, Jules Bordet Institute, ULB, Brussels, Belgium.

Purpose: Amongst the unanswered questions regarding prostate cancer (PCa), the optimal management of oligometastatic disease remains one of the major concerns of the scientific community. The very existence of this category is still subject to controversy. Aim of this systematic review is to summarize current available data on the most appropriate management of oligometastatic PCa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-02652-7DOI Listing
January 2019
2 Reads

Big Data Readiness in Radiation Oncology: An Efficient Approach for Relabeling Radiation Therapy Structures With Their TG-263 Standard Name in Real-World Data Sets.

Adv Radiat Oncol 2019 Jan-Mar;4(1):191-200. Epub 2018 Oct 12.

Australian Institute of Health Innovation, Macquarie University, Sydney, Australia.

Purpose: To prepare for big data analyses on radiation therapy data, we developed a tool-supported approach for standardization of structure names in existing radiation therapy plans. We applied the widely endorsed nomenclature standard TG-263 as the mapping target and quantified the structure name inconsistency in 2 real-world data sets.

Methods And Materials: The clinically relevant structures in the radiation therapy plans were identified by reference to randomized controlled trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2018.09.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349627PMC
October 2018
1 Read

Fixed- versus Variable-RBE Computations for Intensity Modulated Proton Therapy.

Adv Radiat Oncol 2019 Jan-Mar;4(1):156-167. Epub 2018 Dec 13.

Department of Radiation Physics, The University of Texas MD Anderson Cancer, Houston, Texas.

Purpose: To evaluate how using models of proton therapy that incorporate variable relative biological effectiveness (RBE) versus the current practice of using a fixed RBE of 1.1 affects dosimetric indices on treatment plans for large cohorts of patients treated with intensity modulated proton therapy (IMPT).

Methods And Materials: Treatment plans for 4 groups of patients who received IMPT for brain, head-and-neck, thoracic, or prostate cancer were selected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2018.08.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349601PMC
December 2018
1 Read

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.

Adv Radiat Oncol 2019 Jan-Mar;4(1):79-89. Epub 2018 Sep 5.

Department of Radiology, Mayo Clinic, Rochester, Minnesota.

Purpose: Management of recurrent prostate cancer necessitates timely diagnosis and accurate localization of the sites of recurrent disease. The purpose of this study was to assess predictors of histologic outcomes after 11C-choline positron emission tomography/computed tomography (CholPET) to increase the positive predictive value and specificity of CholPET in identifying imaging predictors of malignant and benign nodal disease to better inform clinical decision making regarding local therapy planning.

Materials And Methods: Retrospective review of patients undergoing CholPET followed by percutaneous core needle biopsy between January 1, 2010 and January 1, 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2018.08.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349661PMC
September 2018
1 Read

Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience.

Adv Radiat Oncol 2019 Jan-Mar;4(1):70-78. Epub 2018 Aug 13.

Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.

Purpose: We characterized both physician- and patient-reported rates of gastrointestinal (GI) toxicity in patients treated with proton beam therapy (PBT) at our institution for prostate adenocarcinoma and identified factors associated with toxicity.

Methods And Materials: We treated 192 patients with PBT between July 2013 and July 2016. Included patients had ≥1 year of follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2018.08.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349581PMC
August 2018
1 Read

A feasibility study for predicting optimal radiation therapy dose distributions of prostate cancer patients from patient anatomy using deep learning.

Sci Rep 2019 Jan 31;9(1):1076. Epub 2019 Jan 31.

Medical Artificial Intelligence and Automation Laboratory, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

With the advancement of treatment modalities in radiation therapy for cancer patients, outcomes have improved, but at the cost of increased treatment plan complexity and planning time. The accurate prediction of dose distributions would alleviate this issue by guiding clinical plan optimization to save time and maintain high quality plans. We have modified a convolutional deep network model, U-net (originally designed for segmentation purposes), for predicting dose from patient image contours of the planning target volume (PTV) and organs at risk (OAR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-37741-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355802PMC
January 2019
1 Read

Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial.

Clin Genitourin Cancer 2019 Jan 4. Epub 2019 Jan 4.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada. Electronic address:

Background: The objective of the study was to evaluate the outcomes of clinically localized prostate cancer treated with prostatectomy versus radiation therapy within the context of a prospective prostate cancer screening study.

Patients And Methods: Within the PLCO (Prostate, Lung, Colorectal, and Ovary) trial, patients who were diagnosed with clinically localized prostate cancer and subsequently received treatment with prostatectomy or radiation therapy (with or without hormonal treatment) were included. Univariate and multivariate Cox regression analyses were then performed to determine factors affecting overall and prostate cancer-specific survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.010DOI Listing
January 2019
1 Read